Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study

Wang, Jiaqiang; Gao, Shilei; Yang, Yue; Liu, Xu; Zhang, Peng; Dong, Shuping; Wang, Xin; Yao, Weitao

doi:10.2147/cmar.s337253

Cited by 9 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The distinction of melanoma from CCS is important for treatment decisions to spare patients with CCSs the possible side effects of therapy targeted for instead for melanoma. In comparison to melanoma, the role of immunotherapy is less established in soft tissue sarcomas 25,26 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Compound clear cell sarcoma with EWSR1::CREM fusion

Busam

2023

J Cutan Pathol

View full text Add to dashboard Cite

Cutaneous clear cell sarcomas may be confused with melanomas as a result of overlapping histopathology and immunohistochemical staining. We report a case of a 41‐year‐old woman with a purported history of acral melanoma of the great toe. Twenty‐one months after excision of the primary tumor, the patient developed a groin mass, diagnosed as metastatic melanoma on excision. Five months later, a biopsy of a lung mass was reported as metastatic melanoma. The patient was referred to our institution for treatment, which prompted molecular testing on the groin metastasis by targeted next‐generation sequencing. Molecular testing results revealed TP53 and TERT promoter mutations and the absence of BRAF, KRAS, and KIT mutations; it also revealed an EWSR1::CREM fusion that was confirmed by Archer FusionPlex. The alleged acral melanoma was re‐reviewed, showing an invasive amelanotic spindle cell neoplasm in the dermis with neoplastic nests at the dermal–epidermal junction; the tumor cells expressed markers of melanocytic differentiation but were negative for PRAME and BRAF immunohistochemical staining. Molecular testing of the toe and lung metastasis revealed the same EWSR1::CREM fusion. In light of the molecular findings, the diagnosis was revised to a primary acral compound clear cell sarcoma with EWSR1::CREM fusion.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In comparison to melanoma, the role of immunotherapy is less established in soft tissue sarcomas. 25,26…”

Section: Discussionmentioning

confidence: 99%

Compound clear cell sarcoma with EWSR1::CREM fusion

Busam

2023

J Cutan Pathol

View full text Add to dashboard Cite

show abstract

“…Additionally, another previous study initiated by Wang et al launched a retrospective study to investigate the efficacy of apatinib (another antiangiogenic TKI, similar to anlotinib in China) and camrelizumab (PD-1 blockade) in patients with advanced clear cell sarcoma. 25 A total of 12 patients with advanced clear cell sarcoma who received apatinib or camrelizumab were screened retrospectively. Unfortunately, the efficacy of camrelizumab monotherapy for clear cell sarcoma was limited, which might be different from that in our study.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma

Sun¹,

Xu²,

Xie³

et al. 2022

IJGM

View full text Add to dashboard Cite

This study was to investigate the effectiveness and tolerability of anlotinib plus PD-1 inhibitors for patients with previously treated metastatic soft tissue sarcoma (STS). Methods: Patients with previously treated metastatic STS who were administered with anlotinib plus PD-1 inhibitors in clinical practice were included for analysis retrospectively. All the common subtypes of advanced STS were appropriate for analysis. Efficacy of the regimen was assessed according to the change of target lesion radiologically, and all the patients were followed up regularly. Safety profile during the combination administration was recorded and documented specifically. Clinical significance according to different STS subtypes was analyzed accordingly. Results: From September 2018 to January 2022, a total of 32 patients with previously treated metastatic STS who received anlotinib plus PD-1 blockades were screened for the analysis in this study. The best overall response during the combination administration indicated that partial response was observed in 11 patients, stable disease was noted in 16 patients and progressive disease was found in 6 patients, yielding an objective response rate (ORR) of 34.4% (95% CI: 18.6-53.2%) and a disease control rate (DCR) of 84.4% (95% CI: 67.2-94.7%). Furthermore, the median PFS of 32 patients with metastatic STS was 7.6 months (95% CI: 3.31-11.89) and the median OS was 14.9 months (95% CI: 8.36-21.44). Besides, adverse reactions related to the treatment during anlotinib plus PD-1 inhibitors administration were observed in 29 patients (90.6%), of whom, a total of 13 patients (40.6%) were deemed as grade 3-4 adverse reactions and no grade 5 adverse reaction was found. Specifically, the most common adverse reactions were fatigue, hypertension, hand-foot syndrome, diarrhea and dermal toxicity. Conclusion: Anlotinib plus PD-1 inhibitors demonstrated durable and promising efficacy and tolerable safety for patients with metastatic STS in real world. Further prospective clinical trials were warranted to validate the feasibility of anlotinib plus PD-1 blockades clinically.

show abstract

Camrelizumab/rivoceranib

2022

Reactions Weekly

View full text Add to dashboard Cite

Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study

Cited by 9 publications

References 37 publications

Compound clear cell sarcoma with EWSR1::CREM fusion

Compound clear cell sarcoma with EWSR1::CREM fusion

Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma

Camrelizumab/rivoceranib

Contact Info

Product

Resources

About